Abstract
Adding the glycoprotein IIb/IIIa receptor antagonist tirofiban # to standard treatment for patients with unstable angina pectoris and non-Q-wave myocardial infarction (MI) can significantly reduce ischaemic complications, note researchers from the PRISM * and PRISM-plus * studies. The results of these studies were presented at the 46th Annual Scientific Sessions of the American College of Cardiology [ Anaheim, US; March 1997 ]. Study investigator Dr Harvey White from Green Lane Hospital, Auckland, New Zealand, described the findings as a true ‘ breakthrough ’ in the management of this condition.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
